Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Consolidated Net Income (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Consolidated Net Income for 7 consecutive years, with -$194.6 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 27.21% to -$194.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$704.5 million through Dec 2025, down 33.87% year-over-year, with the annual reading at -$732.9 million for FY2025, 34.89% down from the prior year.
  • Consolidated Net Income hit -$194.6 million in Q4 2025 for BridgeBio Pharma, down from -$185.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$19.1 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
  • Historically, Consolidated Net Income has averaged -$155.4 million across 5 years, with a median of -$163.2 million in 2023.
  • Biggest five-year swings in Consolidated Net Income: surged 86.59% in 2024 and later tumbled 640.71% in 2025.
  • Year by year, Consolidated Net Income stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then increased by 27.21% to -$194.6 million in 2025.
  • Business Quant data shows Consolidated Net Income for BBIO at -$194.6 million in Q4 2025, -$185.0 million in Q3 2025, and -$183.8 million in Q2 2025.